795 related articles for article (PubMed ID: 31242980)
21. Receptor discordances after neoadjuvant chemotherapy and their effects on survival.
Tural D; Karaca M; Zirtiloglu A; M Hacioglu B; Sendur MA; Ozet A
J BUON; 2019; 24(1):20-25. PubMed ID: 30941947
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer.
Manga GP; Shahi PK; Ureña MM; Pereira RQ; Plaza MI; Peron YI; Val RG; Carrión JB; Cañón EP; Alfonso PG
Breast Cancer; 2010 Jul; 17(3):205-11. PubMed ID: 19551465
[TBL] [Abstract][Full Text] [Related]
23. Effect of Obesity on Neoadjuvant Systemic Therapy Outcomes in Patients with Early Breast Cancer: A Retrospective Institutional Study.
Rasmy A; Sorour Y
Asian Pac J Cancer Prev; 2020 Mar; 21(3):683-691. PubMed ID: 32212794
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis.
Miglietta L; Vanella P; Canobbio L; Naso C; Cerisola N; Meszaros P; Parodi MA; Morabito F
Oncology; 2010; 79(3-4):255-61. PubMed ID: 21372600
[TBL] [Abstract][Full Text] [Related]
25. Ki67 expression in breast cancer. Correlation with prognostic markers and clinicopathological parameters in Saudi patients.
Elkablawy MA; Albasri AM; Mohammed RA; Hussainy AS; Nouh MM; Alhujaily AS
Saudi Med J; 2016 Feb; 37(2):137-41. PubMed ID: 26837394
[TBL] [Abstract][Full Text] [Related]
26. The Neutrophil to Lymphocyte Ratio Predicts the Response to Neoadjuvant Chemotherapy in Luminal B Breast Cancer.
Rivas M; Acevedo F; Dominguez F; Galindo H; Camus M; Oddo D; Villarroel A; Razmilic D; Peña J; Munoz Medel M; Navarro ME; Perez-Sepulveda A; Medina L; Merino T; Briones J; Kalergis A; Sanchez C
Asian Pac J Cancer Prev; 2019 Jul; 20(7):2209-2212. PubMed ID: 31350986
[TBL] [Abstract][Full Text] [Related]
27. Hypervascularity Predicts Complete Pathologic Response to Chemotherapy and Late Outcomes in Breast Cancer.
Bufi E; Belli P; Di Matteo M; Giuliani M; Tumino M; Rinaldi P; Nardone L; Franceschini G; Mulé A; Bonomo L
Clin Breast Cancer; 2016 Dec; 16(6):e193-e201. PubMed ID: 27431459
[TBL] [Abstract][Full Text] [Related]
28. Histopathologic correlation of residual mammographic microcalcifications after neoadjuvant chemotherapy for locally advanced breast cancer.
Adrada BE; Huo L; Lane DL; Arribas EM; Resetkova E; Yang W
Ann Surg Oncol; 2015 Apr; 22(4):1111-7. PubMed ID: 25287438
[TBL] [Abstract][Full Text] [Related]
29. Clinical and pathological response to neoadjuvant chemotherapy based on primary tumor reduction is correlated to survival in hormone receptor-positive but not hormone receptor-negative locally advanced breast cancer.
Chen S; Liu Y; Ouyang QW; Huang L; Luo RC; Shao ZM
Ann Surg Oncol; 2015 Jan; 22(1):32-9. PubMed ID: 25012266
[TBL] [Abstract][Full Text] [Related]
30. Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials.
Fontanella C; Lederer B; Gade S; Vanoppen M; Blohmer JU; Costa SD; Denkert C; Eidtmann H; Gerber B; Hanusch C; Hilfrich J; Huober J; Schneeweiss A; Paepke S; Jackisch C; Mehta K; Nekljudova V; Untch M; Neven P; von Minckwitz G; Loibl S
Breast Cancer Res Treat; 2015 Feb; 150(1):127-39. PubMed ID: 25677740
[TBL] [Abstract][Full Text] [Related]
31. Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs.
Demir L; Yigit S; Ellidokuz H; Erten C; Somali I; Kucukzeybek Y; Alacacioglu A; Cokmert S; Can A; Akyol M; Dirican A; Bayoglu V; Sari AA; Tarhan MO
Clin Exp Metastasis; 2013 Dec; 30(8):1047-62. PubMed ID: 23836289
[TBL] [Abstract][Full Text] [Related]
32. The Impact of Facility Volume on Rates of Pathologic Complete Response to Neoadjuvant Chemotherapy Used in Breast Cancer.
Ajmani GS; James TA; Kantor O; Wang CH; Yao KA
Ann Surg Oncol; 2017 Oct; 24(11):3157-3166. PubMed ID: 28685357
[TBL] [Abstract][Full Text] [Related]
33. Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy.
Loibl S; Müller BM; von Minckwitz G; Schwabe M; Roller M; Darb-Esfahani S; Ataseven B; du Bois A; Fissler-Eckhoff A; Gerber B; Kulmer U; Alles JU; Mehta K; Denkert C
Breast Cancer Res Treat; 2011 Nov; 130(2):477-87. PubMed ID: 21837479
[TBL] [Abstract][Full Text] [Related]
34. Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy.
Petruolo OA; Pilewskie M; Patil S; Barrio AV; Stempel M; Wen HY; Morrow M
Ann Surg Oncol; 2017 Sep; 24(9):2556-2562. PubMed ID: 28560596
[TBL] [Abstract][Full Text] [Related]
35. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
36. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
[TBL] [Abstract][Full Text] [Related]
37. Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
Sánchez-Muñoz A; García-Tapiador AM; Martínez-Ortega E; Dueñas-García R; Jaén-Morago A; Ortega-Granados AL; Fernández-Navarro M; de la Torre-Cabrera C; Dueñas B; Rueda AI; Morales F; Ramírez-Torosa C; Martín-Salvago MD; Sánchez-Rovira P
Clin Transl Oncol; 2008 Oct; 10(10):646-53. PubMed ID: 18940745
[TBL] [Abstract][Full Text] [Related]
38. Local radiotherapy alone following neoadjuvant chemotherapy and surgery in combined clinical stage II and III breast cancer.
White R; Dinneen T; Makris A
Radiat Oncol; 2016 Jul; 11():93. PubMed ID: 27457764
[TBL] [Abstract][Full Text] [Related]
39. FOXA1 Expression Significantly Predict Response to Chemotherapy in Estrogen Receptor-Positive Breast Cancer Patients.
Xu C; Wei Q; Guo J; Zhou JC; Mei J; Jiang ZN; Shen JG; Wang LB
Ann Surg Oncol; 2015; 22(6):2034-9. PubMed ID: 25707489
[TBL] [Abstract][Full Text] [Related]
40. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial.
Bonnefoi H; Litière S; Piccart M; MacGrogan G; Fumoleau P; Brain E; Petit T; Rouanet P; Jassem J; Moldovan C; Bodmer A; Zaman K; Cufer T; Campone M; Luporsi E; Malmström P; Werutsky G; Bogaerts J; Bergh J; Cameron DA;
Ann Oncol; 2014 Jun; 25(6):1128-36. PubMed ID: 24618153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
